The introduction of bevacizumab biosimilars has significantly impacted oncology treatment, offering cost-effective alternatives to the reference biologic, Avastin.

Kexing Biopharm, a pioneer in China’s biopharmaceutical company, has officially launched its KX-BODY antibody technology platform.

In the ever-evolving landscape of biopharmaceuticals, Kexing Biopharm stands at the forefront, pioneering advancements in the integration of research and development, production, and sales of innovative drugs.

In the dynamic landscape of the biopharmaceutical industry, innovation and technology play pivotal roles in shaping the future of medicine.

Kexing Biopharm has developed a distinctive biopharma collaboration model that seamlessly integrates cutting-edge technology with a robust service ecosystem—helping partners around the world move faster, reduce risk, and achieve stronger market positions.

Kexing Biopharm has officially entered a new chapter in its global growth journey, transitioning from a traditional export model to a comprehensive, platform-driven globalization strategy.

In an increasingly competitive global pharmaceutical landscape, companies must adopt bold and forward-thinking strategies to remain relevant and competitive.

In the modern pharmaceutical industry, biological products play a crucial role in advancing healthcare and enhancing treatment options.